
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us and our hands-on approach to production and development that sets us apart. If you are looking for a dynamic, innovative, growing company in the biopharmaceutical industry that is committed to excellence and integrity, then consider ADMA Biologics. We currently have an exciting opportunity available for an Center Medical Director - Contractor.
This position reviews and approves all policies and procedures related to donor suitability, donor collection, and donor safety. The Medical Director oversees the medical staff with regard to determination of donor suitability, donor collection and the review of donor test results. The Medical Director provides guidance on a day-to-day basis regarding donor safety issues. The Medical Director may act as the center’s CLIA Laboratory Director. The local center Medical Director must be on-site as needed based on the needs of the center.
The Medical Director follows all FDA, CLIA and OSHA policies and procedures and maintains confidentiality of all personnel, donor, and company information. They assist with the administrative duties to support the Donor Center and maintain compliance with procedures and regulations while following current Good Manufacturing Practices.
The functions of this position include but are not limited to:
Note: The following tasks may also be performed by Technical Consultant as specifically assigned by the CLIA Laboratory Director:
Ability to train others is required.

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.